US2019192480A1PendingUtilityA1

Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof

63
Assignee: ONCOCROSS CO LTDPriority: Aug 28, 2015Filed: Aug 24, 2016Published: Jun 27, 2019
Est. expiryAug 28, 2035(~9.1 yrs left)· nominal 20-yr term from priority
Inventors:Jin Woo Choi
A23L 33/10A23L 2/52A23L 7/10A61P 1/16A61K 31/366A23V 2002/00A23L 13/60A23C 9/1522A61K 31/35A23L 23/00A21D 2/14A61K 31/352
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient. 
     
     
         2 . The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 1 , wherein the cromolyn is a compound represented by below: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 1 , wherein the cromolyn inhibits the accumulation of collagen in hepatic stellate cell (HSC). 
     
     
         4 . The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 1 , wherein the cromolyn inhibits the production of TGF-β in hepatic stellate cell. 
     
     
         5 . The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 1 , wherein the cromolyn inhibits the decrease in expression of E-cadherin in hepatocyte. 
     
     
         6 . The pharmaceutical composition for preventing and treating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 1 , wherein the cromolyn has anti-senescence activity on hepatocytes. 
     
     
         7 . (canceled) 
     
     
         8 . A health food for preventing and ameliorating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis, comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient. 
     
     
         9 . The health food for preventing and ameliorating diseases selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, and hepatitis according to  claim 8 , wherein the cromolyn inhibits the activity of hepatic stellate cell and recovers a hepatocyte function. 
     
     
         10 . (canceled)

Join the waitlist — get patent alerts

Track US2019192480A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.